MARK MIODUSKI — Lobbyist Profile | Poliscope

MARK MIODUSKI

Reported covered position: N/A

Filings

Clients

Firms

Years active

2001–2005

Associated filing income

—

How to read the money

Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.

Clients represented

Client	Filings	Years
BIOGEN	2	2001–2005

Lobbying firms

Firm	Filings	Years
BIOGEN	2	2001–2005

Bills explicitly cited in this lobbyist’s assigned issues (1)

No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.

H.R. 386

Orphan Drug Program Improvement Act of 2001

Client: BIOGEN · Firm: BIOGEN

Open original LDA filing ↗

Cited source text

H.R.386- Orphan Drug Improvement Act

Original LDA source filings (2)

Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.

BIOGEN via BIOGEN

2005 · year_end · YY

Firm income: —Client expense: $380,000Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MMM

Medicare/Medicaid

Food and Drug Administration Safety Act of 2005 Labor HHS and HHS Policy HR 3010 Medicare Coverage and Reimbursement Work related to coverage and payment for Zevalin, including coverage of off label indications

BIOGEN via BIOGEN

2001 · year_end · YY

Firm income: —Client expense: $325,000Open original LDA filing ↗

Source: Senate LDA